Minimizing Membrane Arachidonic Acid Content as a Strategy for Controlling Cancer: A Review

References

• Wang D and DuBois RN: Eicosanoids and cancer. Nat Rev Cancer 10, 181–193, 2010.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, et al.: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376, 1741–1750, 2010.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, et al.: Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 377, 31–41, 2011.
   PubMed Web of Science ®Google Scholar
• Algra AM and Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13, 518–527, 2012.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, et al.: Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379, 1602–1612, 2012.
   PubMed Web of Science ®Google Scholar
• O'Callaghan G and Houston A: Prostaglandin E2 and the EP receptors in malignancy: Possible therapeutic targets? Br J Pharmacol 172, 5239–5250, 2015.
   PubMed Web of Science ®Google Scholar
• Fujino H: The roles of EP4 prostanoid receptors in cancer malignancy signaling. Biol Pharm Bull 39, 149–155, 2016.
   PubMed Web of Science ®Google Scholar
• Ruan D and So SP: Prostaglandin E2 produced by inducible COX-2 and mPGES-1 promoting cancer cell proliferation in vitro and in vivo. Life Sci 116, 43–50, 2014.
   PubMed Web of Science ®Google Scholar
• Reader J, Holt D, and Fulton A: Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev 30, 449–463, 2011.
   PubMed Web of Science ®Google Scholar
• Holt D, Ma X, Kundu N, and Fulton A: Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. Cancer Immunol Immunother 60, 1577–1586, 2011.
   PubMed Web of Science ®Google Scholar
• Zhang Y and Daaka Y: PGE2 promotes angiogenesis through EP4 and PKA Cγ pathway. Blood 118, 5355–5364, 2011.
   PubMed Web of Science ®Google Scholar
• Bishayee K and Khuda-Bukhsh AR: 5-lipoxygenase antagonist therapy: A new approach towards targeted cancer chemotherapy. Acta Biochim Biophys Sin (Shanghai) 45, 709–719, 2013.
   PubMed Web of Science ®Google Scholar
• Ghosh J and Myers CE: Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 95, 13182–13187, 1998.
   PubMed Web of Science ®Google Scholar
• Chen X, Wang S, Wu N, Sood S, Wang P, et al.: Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res 10, 6703–6709, 2004.
   PubMed Web of Science ®Google Scholar
• Poff CD and Balazy M: Drugs that target lipoxygenases and leukotrienes as emerging therapies for asthma and cancer. Curr Drug Targets Inflamm Allergy 3, 19–33, 2004.
   PubMedGoogle Scholar
• Cianchi F, Cortesini C, Magnelli L, Fanti E, Papucci L, et al.: Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther 5, 2716–2726, 2006.
   PubMed Web of Science ®Google Scholar
• Tong WG, Ding XZ, Talamonti MS, Bell RH, and Adrian TE: LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun 335, 949–956, 2005.
   PubMed Web of Science ®Google Scholar
• Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, et al.: Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: A potential target for prevention. Carcinogenesis 26, 785–791, 2005.
   PubMed Web of Science ®Google Scholar
• Bachi AL, Kim FJ, Nonogaki S, Carneiro CR, Lopes JD, et al.: Leukotriene B4 creates a favorable microenvironment for murine melanoma growth. Mol Cancer Res 7, 1417–1424, 2009.
   PubMed Web of Science ®Google Scholar
• Faronato M, Muzzonigro G, Milanese G, Menna C, Bonfigli AR, et al.: Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma. Histol Histopathol 22, 1109–1118, 2007.
   PubMed Web of Science ®Google Scholar
• Park SW, Heo DS, and Sung MW: The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells. Cell Oncol (Dordr) 35, 1–8, 2012.
   PubMed Web of Science ®Google Scholar
• Steinhilber D, Fischer AS, Metzner J, Steinbrink SD, Roos J, et al.: 5-lipoxygenase: Underappreciated role of a pro-inflammatory enzyme in tumorigenesis. Front Pharmacol 1, 143, 2010.
   PubMed Web of Science ®Google Scholar
• Ishii K, Zaitsu M, Yonemitsu N, Kan Y, Hamasaki Y, et al.: 5-lipoxygenase pathway promotes cell proliferation in human glioma cell lines. Clin Neuropathol 28, 445–452, 2009.
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Das S, Roy K, and Chatterjee M: Overexpression of 5-lipoxygenase and its relation with cell proliferation and angiogenesis in 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinogenesis. Mol Carcinog 52, 359–369, 2013.
   PubMed Web of Science ®Google Scholar
• Knab LM, Schultz M, Principe DR, Mascarinas WE, Gounaris E, et al.: Ablation of 5-lipoxygenase mitigates pancreatic lesion development. J Surg Res 194, 481–487, 2015.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Nishiyama K, and Shirahama T: Inhibition of 5-lipoxygenase pathway suppresses the growth of bladder cancer cells. Int J Urol 13, 1086–1091, 2006.
   PubMed Web of Science ®Google Scholar
• Shi HY, Lv FJ, Zhu ST, Wang QG, and Zhang ST: Dual inhibition of 5-LOX and COX-2 suppresses esophageal squamous cell carcinoma. Cancer Lett 309, 19–26, 2011.
   PubMed Web of Science ®Google Scholar
• Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, et al.: Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 26, 827–834, 2005.
   PubMed Web of Science ®Google Scholar
• Klil-Drori AJ and Ariel A: 15-Lipoxygenases in cancer: A double-edged sword? Prostaglandins Other Lipid Mediat 106, 16–22, 2013.
   PubMed Web of Science ®Google Scholar
• Yarla NS, Bishayee A, Sethi G, Reddanna P, Kalle AM, et al.: Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. Semin Cancer Biol 40–41, 48–81, 2016.
   PubMed Web of Science ®Google Scholar
• Chang HH and Meuillet EJ: Identification and development of mPGES-1 inhibitors: Where we are at? Future Med Chem 3, 1909–1934, 2011.
   PubMed Web of Science ®Google Scholar
• DiNicolantonio JJ, McCarty MF, Chatterjee S, Lavie CJ, and O'Keefe JH: A higher dietary ratio of long-chain omega-3 to total omega-6 fatty acids for prevention of COX-2-dependent adenocarcinomas. Nutr Cancer 66, 1279–1284, 2014.
   PubMed Web of Science ®Google Scholar
• Dong L, Zou H, Yuan C, Hong YH, Kuklev DV, et al.: Different fatty acids compete with arachidonic acid for binding to the allosteric or catalytic subunits of cyclooxygenases to regulate prostanoid synthesis. J Biol Chem 291, 4069–4078, 2016.
   PubMed Web of Science ®Google Scholar
• Vecchio AJ, Simmons DM, and Malkowski MG: Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem 285, 22152–22163, 2010.
   PubMed Web of Science ®Google Scholar
• Lands WE, Libelt B, Morris A, Kramer NC, Prewitt TE, et al.: Maintenance of lower proportions of (n - 6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n - 3) fatty acids. Biochim Biophys Acta 1180, 147–162, 1992.
   PubMed Web of Science ®Google Scholar
• Funahashi H, Satake M, Hasan S, Sawai H, Newman RA, et al.: Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Pancreas 36, 353–362, 2008.
   PubMed Web of Science ®Google Scholar
• Hawcroft G, Loadman PM, Belluzzi A, and Hull MA: Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells. Neoplasia 12, 618–627, 2010.
   PubMed Web of Science ®Google Scholar
• Yang P, Chan D, Felix E, Cartwright C, Menter DG, et al.: Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. J Lipid Res 45, 1030–1039, 2004.
   PubMed Web of Science ®Google Scholar
• Yang P, Cartwright C, Chan D, Ding J, Felix E, et al.: Anticancer activity of fish oils against human lung cancer is associated with changes in formation of PGE2 and PGE3 and alteration of Akt phosphorylation. Mol Carcinog 53, 566–577, 2014.
   PubMed Web of Science ®Google Scholar
• Yang P, Jiang Y, and Fischer SM: Prostaglandin E3 metabolism and cancer. Cancer Lett 348, 1–11, 2014.
   PubMed Web of Science ®Google Scholar
• Lee TH, Mencia-Huerta JM, Shih C, Corey EJ, Lewis RA, et al.: Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. J Clin Invest 74, 1922–1933, 1984.
   PubMed Web of Science ®Google Scholar
• Kobayashi J, Yokoyama S, and Kitamura S: Eicosapentaenoic acid modulates arachidonic acid metabolism in rat alveolar macrophages. Prostaglandins Leukot Essent Fatty Acids 52, 259–262, 1995.
   PubMed Web of Science ®Google Scholar
• Xia S, Lu Y, Wang J, He C, Hong S, et al.: Melanoma growth is reduced in fat-1 transgenic mice: Impact of omega-6/omega-3 essential fatty acids. Proc Natl Acad Sci USA 103, 12499–12504, 2006.
   PubMed Web of Science ®Google Scholar
• Jia Q, Lupton JR, Smith R, Weeks BR, Callaway E, et al.: Reduced colitis-associated colon cancer in Fat-1 (n-3 fatty acid desaturase) transgenic mice. Cancer Res 68, 3985–3991, 2008.
   PubMed Web of Science ®Google Scholar
• Lu Y, Nie D, Witt WT, Chen Q, Shen M, et al.: Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3 beta phosphorylation. Mol Cancer Ther 7, 3203–3211, 2008.
   PubMed Web of Science ®Google Scholar
• Lim K, Han C, Dai Y, Shen M, and Wu T: Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther 8, 3046–3055, 2009.
   PubMed Web of Science ®Google Scholar
• Griffitts J, Saunders D, Tesiram YA, Reid GE, Salih A, et al.: Non-mammalian fat-1 gene prevents neoplasia when introduced to a mouse hepatocarcinogenesis model: Omega-3 fatty acids prevent liver neoplasia. Biochim Biophys Acta 1801, 1133–1144, 2010.
   PubMed Web of Science ®Google Scholar
• Weylandt KH, Krause LF, Gomolka B, Chiu CY, Bilal S, et al.: Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-alpha. Carcinogenesis 32, 897–903, 2011.
   PubMed Web of Science ®Google Scholar
• Song KS, Jing K, Kim JS, Yun EJ, Shin S, et al.: Omega-3-polyunsaturated fatty acids suppress pancreatic cancer cell growth in vitro and in vivo via downregulation of Wnt/Beta-catenin signaling. Pancreatology 11, 574–584, 2011.
   PubMed Web of Science ®Google Scholar
• MacLennan MB, Clarke SE, Perez K, Wood GA, Muller WJ, et al.: Mammary tumor development is directly inhibited by lifelong n-3 polyunsaturated fatty acids. J Nutr Biochem 24, 388–395, 2013.
   PubMed Web of Science ®Google Scholar
• Algamas-Dimantov A, Yehuda-Shnaidman E, Hertz R, Peri I, Bar-Tana J, et al.: Prevention of diabetes-promoted colorectal cancer by (n-3) polyunsaturated fatty acids and (n-3) PUFA mimetic. Oncotarget 5, 9851–9863, 2014.
   PubMedGoogle Scholar
• Yao L, Han C, Song K, Zhang J, Lim K, et al.: Omega-3 polyunsaturated fatty acids upregulate 15-PGDH expression in cholangiocarcinoma cells by inhibiting mir-26a/b expression. Cancer Res 75, 1388–1398, 2015.
   PubMed Web of Science ®Google Scholar
• Han YM, Park JM, Cha JY, Jeong M, Go EJ, et al.: Endogenous conversion of omega-6 to omega-3 polyunsaturated fatty acids in fat-1 mice attenuated intestinal polyposis by either inhibiting COX-2/beta-catenin signaling or activating 15-PGDH/IL-18. Int J Cancer 138, 2247–2256, 2016.
   PubMed Web of Science ®Google Scholar
• Zheng H, Tang H, Liu M, He M, Lai P, et al.: Inhibition of endometrial cancer by n-3 polyunsaturated fatty acids in preclinical models. Cancer Prev Res (Phila) 7, 824–834, 2014.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhang Y, Jia C, Wang Y, Lai P, et al.: mTORC1/2 targeted by n-3 polyunsaturated fatty acids in the prevention of mammary tumorigenesis and tumor progression. Oncogene 33, 4548–4557, 2014.
   PubMed Web of Science ®Google Scholar
• Zou Z, Bellenger S, Massey KA, Nicolaou A, Geissler A, et al.: Inhibition of the HER2 pathway by n-3 polyunsaturated fatty acids prevents breast cancer in fat-1 transgenic mice. J Lipid Res 54, 3453–3463, 2013.
   PubMed Web of Science ®Google Scholar
• Zou Z, Bidu C, Bellenger S, Narce M, and Bellenger J: n-3 polyunsaturated fatty acids and HER2-positive breast cancer: Interest of the fat-1 transgenic mouse model over conventional dietary supplementation. Biochimie 96, 22–27, 2014.
   PubMed Web of Science ®Google Scholar
• Mohammed A, Janakiram NB, Brewer M, Duff A, Lightfoot S, et al.: Endogenous n-3 polyunsaturated fatty acids delay progression of pancreatic ductal adenocarcinoma in Fat-1-p48(Cre/+)-LSL-Kras(G12D/+) mice. Neoplasia 14, 1249–1259, 2012.
   PubMed Web of Science ®Google Scholar
• Rahm JJ, and Holman RT: Effect of linoleic acid upon the metabolism of linolenic acid. J Nutr 84, 15–19, 1964.
   PubMed Web of Science ®Google Scholar
• Emken EA, Adlof RO, and Gulley RM: Dietary linoleic acid influences desaturation and acylation of deuterium-labeled linoleic and linolenic acids in young adult males. Biochim Biophys Acta 1213, 277–288, 1994.
   PubMed Web of Science ®Google Scholar
• Chorner Z, Barbeau PA, Castellani L, Wright DC, Chabowski A, et al.: Dietary alpha-linolenic acid supplementation alters skeletal muscle plasma membrane lipid composition, sarcolemmal FAT/CD36 abundance, and palmitate transport rates. Am J Physiol Regul Integr Comp Physiol 311, R1234–R1242, 2016.
   PubMed Web of Science ®Google Scholar
• Horrobin DF: Fatty acid metabolism in health and disease: The role of delta-6-desaturase. Am J Clin Nutr 57, 732S–736S, 1993.
   PubMed Web of Science ®Google Scholar
• Rett BS and Whelan J: Increasing dietary linoleic acid does not increase tissue arachidonic acid content in adults consuming Western-type diets: A systematic review. Nutr Metab (Lond) 8, 36, 2011.
   PubMed Web of Science ®Google Scholar
• Zhao A, Yu J, Lew JL, Huang L, Wright SD, et al.: Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets. DNA Cell Biol 23, 519–526, 2004.
   PubMed Web of Science ®Google Scholar
• Hansen-Petrik MB, McEntee MF, Johnson BT, Obukowicz MG, Masferrer J, et al.: Selective inhibition of Delta-6 desaturase impedes intestinal tumorigenesis. Cancer Lett 175, 157–163, 2002.
   PubMed Web of Science ®Google Scholar
• He C, Qu X, Wan J, Rong R, Huang L, et al.: Inhibiting delta-6 desaturase activity suppresses tumor growth in mice. PLoS One 7, e47567, 2012.
   PubMed Web of Science ®Google Scholar
• Matsuzaka T, Shimano H, Yahagi N, Amemiya-Kudo M, Yoshikawa T, et al.: Dual regulation of mouse Delta(5)- and Delta(6)-desaturase gene expression by SREBP-1 and PPARalpha. J Lipid Res 43, 107–114, 2002.
   PubMed Web of Science ®Google Scholar
• Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, et al.: Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 14, 2819–2830, 2000.
   PubMed Web of Science ®Google Scholar
• Cagen LM, Deng X, Wilcox HG, Park EA, Raghow R, et al.: Insulin activates the rat sterol-regulatory-element-binding protein 1c (SREBP-1c) promoter through the combinatorial actions of SREBP, LXR, Sp-1 and NF-Y cis-acting elements. Biochem J 385, 207–216, 2005.
   PubMed Web of Science ®Google Scholar
• Serviddio G, Blonda M, Bellanti F, Villani R, Iuliano L, et al.: Oxysterols and redox signaling in the pathogenesis of non-alcoholic fatty liver disease. Free Radic Res 47, 881–893, 2013.
   PubMed Web of Science ®Google Scholar
• Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, et al.: Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93, 693–704, 1998.
   PubMed Web of Science ®Google Scholar
• Peet DJ, Janowski BA, and Mangelsdorf DJ: The LXRs: A new class of oxysterol receptors. Curr Opin Genet Dev 8, 571–575, 1998.
   PubMed Web of Science ®Google Scholar
• Basciano H, Miller AE, Naples M, Baker C, Kohen R, et al.: Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am J Physiol Endocrinol Metab 297, E462–E473, 2009.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Miyazaki M, Man WC, and Ntambi JM: Sterol regulatory element-binding proteins (SREBPs) as regulators of lipid metabolism: Polyunsaturated fatty acids oppose cholesterol-mediated induction of SREBP-1 maturation. Ann N Y Acad Sci 967, 34–42, 2002.
   PubMed Web of Science ®Google Scholar
• Beltowski J: Liver X receptors (LXR) as therapeutic targets in dyslipidemia. Cardiovasc Ther 26, 297–316, 2008.
   PubMed Web of Science ®Google Scholar
• Edwards JE and Moore RA: Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 4, 18, 2003.
   PubMedGoogle Scholar
• Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, et al.: A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6, 517–526, 2000.
   PubMed Web of Science ®Google Scholar
• Brendel C, Schoonjans K, Botrugno OA, Treuter E, and Auwerx J: The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. Mol Endocrinol 16, 2065–2076, 2002.
   PubMed Web of Science ®Google Scholar
• Seol W, Chung M, and Moore DD: Novel receptor interaction and repression domains in the orphan receptor SHP. Mol Cell Biol 17, 7126–7131, 1997.
   PubMed Web of Science ®Google Scholar
• Lee YS, Chanda D, Sim J, Park YY, and Choi HS: Structure and function of the atypical orphan nuclear receptor small heterodimer partner. Int Rev Cytol 261, 117–158, 2007.
   PubMedGoogle Scholar
• Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, et al.: Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113, 1408–1418, 2004.
   PubMed Web of Science ®Google Scholar
• Hubbert ML, Zhang Y, Lee FY, and Edwards PA: Regulation of hepatic Insig-2 by the farnesoid X receptor. Mol Endocrinol 21, 1359–1369, 2007.
   PubMedGoogle Scholar
• Yabe D, Brown MS, and Goldstein JL: Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc Natl Acad Sci U S A 99, 12753–12758, 2002.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Takahashi M, and Ezaki O: Fish oil feeding decreases mature sterol regulatory element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse liver. A possible mechanism for down-regulation of lipogenic enzyme mRNAs. J Biol Chem 274, 25892–25898, 1999.
   PubMed Web of Science ®Google Scholar
• Gani OA and Sylte I: Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha. J Mol Graph Model 27, 217–224, 2008.
   PubMed Web of Science ®Google Scholar
• Videla LA, Fernandez V, Vargas R, Cornejo P, Tapia G, et al.: Upregulation of rat liver PPARalpha-FGF21 signaling by a docosahexaenoic acid and thyroid hormone combined protocol. Biofactors 42, 638–646, 2016.
   PubMed Web of Science ®Google Scholar
• Zhu H, Fan C, Xu F, Tian C, Zhang F, et al.: Dietary fish oil n-3 polyunsaturated fatty acids and alpha-linolenic acid differently affect brain accretion of docosahexaenoic acid and expression of desaturases and sterol regulatory element-binding protein 1 in mice. J Nutr Biochem 21, 954–960, 2010.
   PubMed Web of Science ®Google Scholar
• Lamaziere A, Wolf C, Barbe U, Bausero P, and Visioli F: Lipidomics of hepatic lipogenesis inhibition by omega 3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 88, 149–154, 2013.
   PubMed Web of Science ®Google Scholar
• Njoroge SW, Laposata M, Katrangi W, and Seegmiller AC: DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity. J Lipid Res 53, 257–265, 2012.
   PubMed Web of Science ®Google Scholar
• Gronn M, Christensen E, Hagve TA, and Christophersen BO: Effects of dietary purified eicosapentaenoic acid (20:5 (n-3)) and docosahexaenoic acid (22:6(n-3)) on fatty acid desaturation and oxidation in isolated rat liver cells. Biochim Biophys Acta 1125, 35–43, 1992.
   PubMed Web of Science ®Google Scholar
• Yap F, Craddock L, and Yang J: Mechanism of AMPK suppression of LXR-dependent Srebp-1c transcription. Int J Biol Sci 7, 645–650, 2011.
   PubMed Web of Science ®Google Scholar
• Sozio MS, Lu C, Zeng Y, Liangpunsakul S, and Crabb DW: Activated AMPK inhibits PPAR-{alpha} and PPAR-{gamma} transcriptional activity in hepatoma cells. Am J Physiol Gastrointest Liver Physiol 301, G739–G747, 2011.
   PubMed Web of Science ®Google Scholar
• Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans A, et al.: Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 11, 554–565, 2010.
   PubMed Web of Science ®Google Scholar
• Hardie DG, Ross FA, and Hawley SA: AMP-activated protein kinase: A target for drugs both ancient and modern. Chem Biol 19, 1222–1236, 2012.
   PubMed Web of Science ®Google Scholar
• Gong J, Kelekar G, Shen J, Shen J, Kaur S, et al.: The expanding role of metformin in cancer: An update on antitumor mechanisms and clinical development. Target Oncol 11, 447–467, 2016.
   PubMed Web of Science ®Google Scholar
• Wang N, Tan HY, Li L, Yuen MF, and Feng Y: Berberine and coptidis rhizoma as potential anticancer agents: Recent updates and future perspectives. J Ethnopharmacol 176, 35–48, 2015.
   PubMed Web of Science ®Google Scholar
• Akhtar MS, Ramzan A, Ali A, and Ahmad M: Effect of Amla fruit (Emblica officinalis Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. Int J Food Sci Nutr 62, 609–616, 2011.
   PubMed Web of Science ®Google Scholar
• Antony B, Benny M, and Kaimal TN: A Pilot clinical study to evaluate the effect of Emblica officinalis extract (Amlamax) on markers of systemic inflammation and dyslipidemia. Indian J Clin Biochem 23, 378–381, 2008.
   PubMedGoogle Scholar
• Yokozawa T, Kim HY, Kim HJ, Okubo T, Chu DC, et al.: Amla (Emblica officinalis Gaertn.) prevents dyslipidaemia and oxidative stress in the ageing process. Br J Nutr 97, 1187–1195, 2007.
   PubMed Web of Science ®Google Scholar
• Kim HY, Okubo T, Juneja LR, and Yokozawa T: The protective role of amla (Emblica officinalis Gaertn.) against fructose-induced metabolic syndrome in a rat model. Br J Nutr 103, 502–512, 2010.
   PubMed Web of Science ®Google Scholar
• Koshy SM, Bobby Z, Hariharan AP, and Gopalakrishna SM: Amla (Emblica officinalis) extract is effective in preventing high fructose diet-induced insulin resistance and atherogenic dyslipidemic profile in ovariectomized female albino rats. Menopause 19, 1146–1155, 2012.
   PubMed Web of Science ®Google Scholar
• Koshy SM, Bobby Z, Jacob SE, Ananthanarayanan PH, Sridhar MG, et al.: Amla prevents fructose-induced hepatic steatosis in ovariectomized rats: Role of liver FXR and LXRalpha. Climacteric 18, 299–310, 2015.
   PubMed Web of Science ®Google Scholar
• De A, De A, Papasian C, Hentges S, Banerjee S, et al.: Emblica officinalis extract induces autophagy and inhibits human ovarian cancer cell proliferation, angiogenesis, growth of mouse xenograft tumors. PLoS One 8, e72748, 2013.
   PubMed Web of Science ®Google Scholar
• Zhao T, Sun Q, Marques M, Witcher M: Anticancer Properties of Phyllanthus emblica (Indian Gooseberry). Oxid Med Cell Longev 2015, 950890, 2015.
   PubMed Web of Science ®Google Scholar
• Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, et al.: Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 99, 11908–11913, 2002.
   PubMed Web of Science ®Google Scholar
• Kay HY, Kim WD, Hwang SJ, Choi HS, Gilroy RK, et al.: Nrf2 inhibits LXRalpha-dependent hepatic lipogenesis by competing with FXR for acetylase binding. Antioxid Redox Signal 15, 2135–2146, 2011.
   PubMed Web of Science ®Google Scholar
• Oh GS, Lee GG, Yoon J, Oh WK, and Kim SW: Selective inhibition of liver X receptor alpha-mediated lipogenesis in primary hepatocytes by licochalcone A. Chin Med 10, 8, 2015.
   PubMed Web of Science ®Google Scholar
• Yabe D, Komuro R, Liang G, Goldstein JL, and Brown MS: Liver-specific mRNA for Insig-2 down-regulated by insulin: Implications for fatty acid synthesis. Proc Natl Acad Sci USA 100, 3155–3160, 2003.
   PubMed Web of Science ®Google Scholar
• Deng X, Yellaturu C, Cagen L, Wilcox HG, Park EA, et al.: Expression of the rat sterol regulatory element-binding protein-1c gene in response to insulin is mediated by increased transactivating capacity of specificity protein 1 (Sp1). J Biol Chem 282, 17517–17529, 2007.
   PubMed Web of Science ®Google Scholar
• Deng X, Zhang W, Sullivan I, Williams JB, Dong Q, et al.: FoxO1 inhibits sterol regulatory element-binding protein-1c (SREBP-1c) gene expression via transcription factors Sp1 and SREBP-1c. J Biol Chem 287, 20132–20143, 2012.
   PubMed Web of Science ®Google Scholar
• Olsen A, Christensen J, Knudsen KE, Johnsen NF, Overvad K, et al.: Prediagnostic plasma enterolactone levels and mortality among women with breast cancer. Breast Cancer Res Treat 128, 883–889, 2011.
   PubMed Web of Science ®Google Scholar
• Buck K, Vrieling A, Zaineddin AK, Becker S, Hüsing A, et al.: Serum enterolactone and prognosis of postmenopausal breast cancer. J Clin Oncol 29, 3730–3738, 2011.
   PubMed Web of Science ®Google Scholar
• Guglielmini P, Rubagotti A, and Boccardo F: Serum enterolactone levels and mortality outcome in women with early breast cancer: A retrospective cohort study. Breast Cancer Res Treat 132, 661–668, 2012.
   PubMed Web of Science ®Google Scholar
• Seibold P, Vrieling A, Johnson TS, Buck K, Behrens S, et al.: Enterolactone concentrations and prognosis after postmenopausal breast cancer: Assessment of effect modification and meta-analysis. Int J Cancer 135, 923–933, 2014.
   PubMed Web of Science ®Google Scholar
• Wang L, Chen J, and Thompson LU: The inhibitory effect of flaxseed on the growth and metastasis of estrogen receptor negative human breast cancer xenograftsis attributed to both its lignan and oil components. Int J Cancer 116, 793–798, 2005.
   PubMed Web of Science ®Google Scholar
• Thompson LU, Chen JM, Li T, Strasser-Weippl K, and Goss PE: Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res 11, 3828–3835, 2005.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang L, and Thompson LU: Flaxseed and its components reduce metastasis after surgical excision of solid human breast tumor in nude mice. Cancer Lett 234, 168–175, 2006.
   PubMed Web of Science ®Google Scholar
• Bergman JM, Thompson LU, and Dabrosin C: Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res 13, 1061–1067, 2007.
   PubMed Web of Science ®Google Scholar
• Chen J, Saggar JK, Corey P, and Thompson LU: Flaxseed and pure secoisolariciresinol diglucoside, but not flaxseed hull, reduce human breast tumor growth (MCF-7) in athymic mice. J Nutr 139, 2061–2066, 2009.
   PubMed Web of Science ®Google Scholar
• Saggar JK, Chen J, Corey P, and Thompson LU: The effect of secoisolariciresinol diglucoside and flaxseed oil, alone and in combination, on MCF-7 tumor growth and signaling pathways. Nutr Cancer 62, 533–542, 2010.
   PubMed Web of Science ®Google Scholar
• Mabrok HB, Klopfleisch R, Ghanem KZ, Clavel T, Blaut M, et al.: Lignan transformation by gut bacteria lowers tumor burden in a gnotobiotic rat model of breast cancer. Carcinogenesis 33, 203–208, 2012.
   PubMed Web of Science ®Google Scholar
• Chen J, Stavro PM, and Thompson LU: Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutr Cancer 43, 187–192, 2002.
   PubMed Web of Science ®Google Scholar
• Truan JS, Chen JM, and Thompson LU: Flaxseed oil reduces the growth of human breast tumors (MCF-7) at high levels of circulating estrogen. Mol Nutr Food Res 54, 1414–1421, 2010.
   PubMed Web of Science ®Google Scholar
• Lowcock EC, Cotterchio M, and Boucher BA: Consumption of flaxseed, a rich source of lignans, is associated with reduced breast cancer risk. Cancer Causes Control 24, 813–816, 2013.
   PubMed Web of Science ®Google Scholar
• Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, et al.: Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev 17, 3577–3587, 2008.
   PubMed Web of Science ®Google Scholar
• Azrad M, Vollmer RT, Madden J, Dewhirst M, Polascik TJ, et al.: Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer. J Med Food 16, 357–360, 2013.
   PubMed Web of Science ®Google Scholar
• Lin X, Gingrich JR, Bao W, Li J, Haroon ZA, et al.: Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice. Urology 60, 919–924, 2002.
   PubMed Web of Science ®Google Scholar
• Park SY, Murphy SP, Wilkens LR, Henderson BE, and Kolonel LN: Fat and meat intake and prostate cancer risk: The multiethnic cohort study. Int J Cancer 121, 1339–1345, 2007.
   PubMed Web of Science ®Google Scholar
• Fu YQ, Zheng JS, Yang B, and Li D: Effect of individual omega-3 fatty acids on the risk of prostate cancer: A systematic review and dose-response meta-analysis of prospective cohort studies. J Epidemiol 25, 261–274, 2015.
   PubMed Web of Science ®Google Scholar
• Giordano C, Catalano S, Panza S, Vizza D, Barone I, et al.: Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene 30, 4129–4140, 2011.
   PubMed Web of Science ®Google Scholar
• Menendez JA, Vazquez-Martin A, Ropero S, Colomer R, and Lupu R: HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: The "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail". Clin Transl Oncol 8, 812–820, 2006.
   PubMedGoogle Scholar
• Mason JK, Chen J, and Thompson LU: Flaxseed oil-trastuzumab interaction in breast cancer. Food Chem Toxicol 48, 2223–2226, 2010.
   PubMed Web of Science ®Google Scholar
• Mason JK, Fu M, Chen J, and Thompson LU: Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474). J Nutr Biochem 26, 16–23, 2015.
   PubMed Web of Science ®Google Scholar
• Liu J, Tong SJ, Wang X, and Qu LX: Farnesoid X receptor inhibits LNcaP cell proliferation via the upregulation of PTEN. Exp Ther Med 8, 1209–1212, 2014.
   PubMed Web of Science ®Google Scholar
• Ghosh-Choudhury T, Mandal CC, Woodruff K, St Clair P, Fernandes G, et al.: Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth. Breast Cancer Res Treat 118, 213–228, 2009.
   PubMed Web of Science ®Google Scholar
• Sayanova O and Napier JA: Transgenic oilseed crops as an alternative to fish oils. Prostaglandins Leukot Essent Fatty Acids 85, 253–260, 2011.
   PubMed Web of Science ®Google Scholar
• Petrie JR, Shrestha P, Zhou XR, Mansour MP, Liu Q, et al.: Metabolic engineering plant seeds with fish oil-like levels of DHA. PLoS One 7, e49165, 2012.
   PubMed Web of Science ®Google Scholar
• Mansour MP, Shrestha P, Belide S, Petrie JR, Nichols PD, et al.: Characterization of oilseed lipids from "DHA-producing Camelina sativa": A new transformed land plant containing long-chain omega-3 oils. Nutrients 6, 776–789, 2014.
   PubMed Web of Science ®Google Scholar
• Ruiz-Lopez N, Haslam RP, Napier JA, and Sayanova O: Successful high-level accumulation of fish oil omega-3 long-chain polyunsaturated fatty acids in a transgenic oilseed crop. Plant J 77, 198–208, 2014.
   PubMed Web of Science ®Google Scholar
• Tejera N, Vauzour D, Betancor MB, Sayanova O, Usher S, et al.: A transgenic camelina sativa seed oil effectively replaces fish oil as a dietary source of eicosapentaenoic acid in mice. J Nutr 146, 227–235, 2016.
   PubMed Web of Science ®Google Scholar
• Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, et al.: Metformin and cancer risk and mortality: A systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) 7, 867–885, 2014.
   PubMed Web of Science ®Google Scholar
• Azrad M, Zhang K, Vollmer RT, Madden J, Polascik TJ, et al.: Prostatic alpha-linolenic acid (ALA) is positively associated with aggressive prostate cancer: A relationship which may depend on genetic variation in ALA metabolism. PLoS One 7, e53104, 2012.
   PubMed Web of Science ®Google Scholar
• Winnik S, Lohmann C, Richter EK, Schäfer N, Song WL, et al.: Dietary alpha-linolenic acid diminishes experimental atherogenesis and restricts T cell-driven inflammation. Eur Heart J 32, 2573–2584, 2011.
   PubMed Web of Science ®Google Scholar
• Fukumitsu S, Aida K, Ueno N, Ozawa S, Takahashi Y, et al.: Flaxseed lignan attenuates high-fat diet-induced fat accumulation and induces adiponectin expression in mice. Br J Nutr 100, 669–676, 2008.
   PubMed Web of Science ®Google Scholar
• Dupasquier CM, Dibrov E, Kneesh AL, Cheung PK, Lee KG, et al.: Dietary flaxseed inhibits atherosclerosis in the LDL receptor-deficient mouse in part through antiproliferative and anti-inflammatory actions. Am J Physiol Heart Circ Physiol 293, H2394–H2402, 2007.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Oda E, Sano T, Yamashita T, Ijiru Y, et al.: Varying the ratio of dietary n-6/n-3 polyunsaturated fatty acid alters the tendency to thrombosis and progress of atherosclerosis in apoE-/- LDLR-/- double knockout mouse. Thromb Res 116, 393–401, 2005.
   PubMed Web of Science ®Google Scholar
• Hageman J, Herrema H, Groen AK, and Kuipers F: A role of the bile salt receptor FXR in atherosclerosis. Arterioscler Thromb Vasc Biol 30, 1519–1528, 2010.
   PubMed Web of Science ®Google Scholar
• Mencarelli A and Fiorucci S: FXR an emerging therapeutic target for the treatment of f atherosclerosis. J Cell Mol Med 14, 79–92, 2010.
   PubMed Web of Science ®Google Scholar
• Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, et al.: Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J Lipid Res 50, 1090–1100, 2009.
   PubMed Web of Science ®Google Scholar
• Zhang J, Grieger JA, Kris-Etherton PM, Thompson JT, Gillies PJ, et al.: Walnut oil increases cholesterol efflux through inhibition of stearoyl CoA desaturase 1 in THP-1 macrophage-derived foam cells. Nutr Metab (Lond) 8, 61, 2011.
   PubMed Web of Science ®Google Scholar
• Prasad K and adhav A: Prevention and treatment of atherosclerosis with flaxseed-derived compound secoisolariciresinol diglucoside. Curr Pharm Des 22, 214–220, 2015.
   Web of Science ®Google Scholar
• Prasad K: Regression of hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Atherosclerosis 197, 34–42, 2008.
   PubMed Web of Science ®Google Scholar
• Fischer S and Weber PC: Prostaglandin I3 is formed in vivo in man after dietary eicosapentaenoic acid. Nature 307, 165–168, 1984.
   PubMed Web of Science ®Google Scholar
• Kobzar G, Mardla V, Jarving I, and Samel N: Comparison of anti-aggregatory effects of PGI2, PGI3 and iloprost on human and rabbit platelets. Cell Physiol Biochem 11, 279–284, 2001.
   PubMed Web of Science ®Google Scholar
• Ruan CH, So SP, and Ruan KH: Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: Mechanisms of COX-2 inhibitor risk to heart disease. Life Sci 88, 24–30, 2011.
   PubMed Web of Science ®Google Scholar
• Funk CD and FitzGerald GA: COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 50, 470–479, 2007.
   PubMed Web of Science ®Google Scholar
• Goyal A, Sharma V, Upadhyay N, Gill S, and Sihag M: Flax and flaxseed oil: An ancient medicine & modern functional food. J Food Sci Technol 51, 1633–1653, 2014.
   PubMed Web of Science ®Google Scholar